Date: 2017-03-21
Type of information: Nomination
Compound:
Company: Oramed Pharmaceuticals (Israel)
Therapeutic area: Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 21, 2017, Oramed Pharmaceuticals announced the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer. Dr. Ronald Law has over 25 years of academic and pharmaceutical industry experience in diabetes, cardiovascular disease, and obesity. During his industry career at Takeda Pharmaceuticals, Dr. Law served in a variety of leadership and strategic roles spanning US Medical Affairs, Global Medical Affairs, Corporate Strategic Planning, Global Scientific Affairs and Intelligence, and R&D External Innovation. Prior to joining Takeda, Dr. Law was an Associate Professor of Medicine in the Endocrinology Division, UCLA School of Medicine. Dr. Law received a PhD in Molecular Biology from UCLA and a JD from the Whittier College School of Law. He is a member of the American Diabetes Association and the American Heart Association.
Financial terms:
Latest news:
Is general: Yes
